Optimization of busulfan dosage in children undergoing bone marrow transplantation: a pharmacokinetic study of dose escalation.

@article{Yeager1992OptimizationOB,
  title={Optimization of busulfan dosage in children undergoing bone marrow transplantation: a pharmacokinetic study of dose escalation.},
  author={Andrew M. Yeager and John E Wagner and Michael L. Graham and Richard M. Jones and George W. Santos and Louise B. Grochow},
  journal={Blood},
  year={1992},
  volume={80 9},
  pages={2425-8}
}
Busulfan (BU) is a widely used myeloablative and antineoplastic agent in clinical bone marrow transplantation (BMT). The lower incidence of BU-associated toxicities and lower therapeutic effectiveness in young children given BU doses based on body weight (ie, 16 mg/kg) is associated with altered pharmacokinetics of BU; the area under the curve (AUC) of BU concentration versus time is significantly less in these patients than those observed in older children and adults. To optimize BU dosage in… CONTINUE READING